# CodeBreaK 202 (NCT05920356)

> A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05920356
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Amgen
- Conditions: Non-Small Cell Lung Cancer (NSCLC)
- Interventions: Sotorasib; Pembrolizumab
- Enrollment: 750
- Primary outcome: Progression-free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 5
- YouTube: 4
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=codebreak-202-nct05920356

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05920356", "email": "<work email>"}; the inbox owner confirms by the emailed link.